NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020.

BrainStorms CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer and Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. EDT, Tuesday, May 5, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 1Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

ABOUT NUROWNNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

ABOUT BRAINSTORM CELL THERAPEUTICS INC.:BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

SAFE HARBOR STATEMENT:Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTSInvestor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

See the original post:
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace

Bone Marrow Stem Cells Comments Off on BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT – BioSpace | April 30th, 2020

DURHAM, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Companys initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).

DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.1

Given the severity of the COVID-19 pandemic, we have evaluated many potential targets to address the clinical manifestations associated with severe COVID-19,said Joseph Lasky, M.D., Professor of Medicine, Pulmonary and Critical Care Section Chief, John W. Deming, M.D. Endowed Chair in Internal Medicine at Tulane University Medical School. Based on the literature, we believe DSTAT has the potential to reduce the excessive inflammation, immune cell infiltration and hypercoagulation associated with poor outcomes in patients with severe COVID-19 infection.

DSTAT is well-suited to unlock the anti-inflammatory properties of heparin as it may be dosed at much higher levels than any available form of heparin without triggering bleeding complications, said Mike Sherman, Chief Executive Officer of Chimerix. We had planned to evaluate DSTAT in several indications of high unmet need, including ALI from different causes. The pandemic intensified our focus on ALI associated with COVID-19. Our team has worked closely with critical care physicians treating COVID-19 patients and with the U.S. Food and Drug Administration (FDA) to develop a Phase 2/3 protocol to determine if DSTAT can reduce the need for mechanical ventilation and improve the rate of survival in patients with severe COVID-19 infection.

Phase 2/3 Study Design

The study is a 1:1 randomized, double-blind, placebo-controlled, Phase 2/3 trial to determine the safety and efficacy of DSTAT in adults with severe COVID-19 who are at high risk of respiratory failure. Eligible subjects will be those with confirmed COVID-19 who require hospitalization and supplemental oxygen therapy. The primary endpoint of the study is the proportion of subjects who survive and do not require mechanical ventilation through day 28. Additional endpoints include time to improvement as assessed by the National Institute of Allergy and Infectious Disease ordinal scale, time to hospital discharge, time to resolution of fever, number of ventilator-free days, all-cause mortality, and changes in key biomarkers (e.g. interleukin-6 (IL-6), tumor necrosis factor- (TNF-), high mobility group box 1 (HMGB1), C-reactive protein and d-dimer).

The Phase 2 portion of the study will enroll 24 subjects to confirm the maximum safe dose and will then expand by an additional 50 patients (74 total) at the selected dose. A formal analysis of all endpoints, including supportive biomarkers will be performed at the conclusion of the phase 2 portion of the study. Contingent upon positive results, the Phase 3 portion of the study will enroll approximately 450 subjects.

Clinical Rationale for DSTAT in COVID-19 Patients with ALI

The clinical manifestations of COVID-19 range from mild, self-limited respiratory tract illness to severe alveolar damage and progressive respiratory failure, multiple organ failure, and death. Mortality in COVID-19 is associated with severe pulmonary disease and coagulation disorders such as disseminated intravascular coagulation (DIC).2,3

The mechanistic rationale supporting DSTATs potential in ALI patients with COVID-19 is two-fold:

In a recent Phase 2 Acute Myeloid Leukemia (AML) study DSTAT was well tolerated with adverse events similar across DSTAT and control groups. DSTAT is an investigational agent, not yet licensed or approved for use.

Conference Call and Webcast

Chimerix will host a conference call and live audio webcast today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 8263766.

A live audio webcast of the call will also be available on the Investors section of Chimerixs website, http://www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

Dociparstat sodium is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity In vitro and in vivo animal model data support DSTATs potential to reduce the inflammation and cellular infiltration associated with acute lung injury and address coagulation disorders associated with COVID-19 pathology. Separately, DSTAT inhibits the activities of several key proteins implicated in the viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy (e.g., CXCL12, selectins, HMGB1, elastase). Randomized Phase 2 data suggest that DSTAT may also accelerate platelet recovery post-chemotherapy via inhibition of PF4, a negative regulator of platelet production that impairs platelet recovery following chemotherapy. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, http://www.chimerix.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the mechanism of action of DSTAT and its potential in ALI patients with COVID-19; Chimerixs ability to develop DSTAT, including the initiation of a Phase 2/3 clinical trial for DSTAT as a potential treatment for ALI associated with COVID-19; and Chimerixs ability to submit and/or obtain regulatory approvals for DSTAT. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that DSTAT may not achieve the endpoints of the Phase 2/3 clinical trial; risks that DSTAT may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that development activities related to DSTAT may not be completed on time or at all; Chimerixs reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:Investor Relations:Michelle LaSpaluto919 972-7115ir@chimerix.com

Will OConnorStern Investor Relationswill@sternir.com212-362-1200

Media:David SchullRusso Partners858-717-2310david.schull@russopartnersllc.com

note: DSTAT may be referred to as 2-O,3-O desulfated heparin, ODSH or CX-01 in these references.

Excerpt from:
Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 - BioSpace

Bone Marrow Stem Cells Comments Off on Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 – BioSpace | April 30th, 2020

VANCOUVER, Washington, April 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic services provider and an advisor to CytoDyn, will provide a comprehensive update on leronlimab for COVID-19. The Wall Street Reporter's event is scheduled for Friday, May 1, 2020 at 12:30 pm ET / 9:30 am PT.

Dr. Pourhassan will provide an update on patient enrollment in eIND, Phase 2 and Phase 2b/3 COVID-19 trials. Dr. Patterson will discuss his latest discovery of the mechanism of action of COVID-19 and the effect of leronlimab.

Interested participants are encouraged to login early prior to the start of the event, as the online event has a capacity of 3,000 participants and the Company's recent investment community conference call had over 3,600 participants. The livestream presentation will be archived for 30 days. For anyone unable to attend, a video will be posted on CytoDyn's website approximately 24 hours after the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.

About Coronavirus Disease 2019CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a "Fast Track" designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted "orphan drug" designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells.The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Company's cash position, (ii)the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv)the Company's ability to enter into partnership or licensing arrangements with third parties, (v)the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Company's ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Company's clinical trials, (viii)the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

More here:
CytoDyn's Drs. Pourhassan and Patterson to Present Live at Wall Street Reporter's Event to Discuss Paper Recently Submitted for Publication and...

Bone Marrow Stem Cells Comments Off on CytoDyn’s Drs. Pourhassan and Patterson to Present Live at Wall Street Reporter’s Event to Discuss Paper Recently Submitted for Publication and… | April 30th, 2020

Central to a lot of scientific research into aging are tiny caps on the ends of our chromosomes called telomeres. These protective sequences of DNA grow a little shorter each time a cell divides, but by intervening in this process, researchers hope to one day regulate the process of aging and the ill health effects it can bring. A Harvard team is now offering an exciting pathway forward, discovering a set of small molecules capable of restoring telomere length in mice.

Telomeres can be thought of like the plastic tips on the end of our shoelaces, preventing the fraying of the DNA code of the genome and playing an important part in a healthy aging process. But each time a cell divides, they grow a little shorter. This sequence repeats over and over until the cell can no longer divide and dies.

This process is linked to aging and disease, including a rare genetic disease called dyskeratosis congenita (DC). This is caused by the premature aging of cells and is where the team focused its attention, hoping to offer alternatives to the current treatment that involves high-risk bone marrow transplants and which offers limited benefits.

One of the ways dyskeratosis congenita comes about is through genetic mutations that disrupt an enzyme called telomerase, which is key to maintaining the structural integrity of the telomere caps. For this reason, researchers have been working to target telomerase for decades, in hopes of finding ways to slow or even reverse the effects of aging and diseases like dyskeratosis congenita.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Boston Childrens Hospitals Suneet Agarwal, senior investigator on the new study. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

Agarwal has been studying the biology of telomerase for the past decade, and back in 2015 he and his team discovered a gene called PARN that plays a role in the action of the telomerase enzyme. This gene normally processes and stabilizes an important component of telomerase called TERC, but when it mutates, it results in less of the enzyme being produced and, in turn, the telomeres becoming shortened prematurely. For the new study, researchers screened more than 100,000 known chemicals in search of compounds that could preserve healthy function of PARN. This led them to a small handful that seemed capable of doing so by inhibiting an enzyme called PAPD5, which serves to unravel PARN and destabilize TERC.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Harvard Medical Schools Neha Nagpal, first author on the new paper. These chemicals were tested on stem cells in the lab, made from the cells of patients with dyskeratosis congenita.

Read the rest here:
Molecules identified that reverse cellular aging process - Daily Times

Bone Marrow Stem Cells Comments Off on Molecules identified that reverse cellular aging process – Daily Times | April 28th, 2020

A Co Armagh cancer survivor is inspiring people to Race for Life at Home and carry on the fight against the disease in these unprecedented times.

Clare Crossey (33), a care worker from Lurgan who was diagnosed with leukaemia in February 2018, had hoped to take part in Cancer Research UK's Race for Life in Belfast on Sunday, May 24.

Unfortunately the Belfast Race for Life is among events which organisers Cancer Research UK have postponed this spring and summer to protect the country's health during the coronavirus outbreak.

But as the nation's lockdown continues, undeterred women and men are already vowing to carry on and complete a Race for Life at Home challenge in their garden or their nearest green space.

Clare is unable to take up the challenge right now, as she is recovering from a bone marrow transplant, but is determined to lend her support and has recruited her sister Alison and daughters Meabh (8) and Lily (11) - who are limbering up with Joe Wicks on YouTube every morning.

The mum-of-two's life changed very suddenly in February 2018 when she was diagnosed with acute myeloid leukaemia, a cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells.

She has faced a tough battle for survival over the past two years and this time last year was in isolation receiving treatment and a stem cell transplant.

As she now faces isolation again to protect herself from coronavirus, Clare is remaining upbeat.

She says: "I now have a brand new immune system, almost like I have been reborn, so I need to have all the injections a new baby has.

"This places me at especially high risk from the coronavirus. It is frightening, but with the help of family, I am being very careful.

"We're all going to be spending a lot of time indoors this spring, so it feels good to take back some control and plan something positive to help me and to help people who are going through cancer right now.

"That's why I am happy to ask people to please join in the fun and still feel part of the Race for Life community."

Clare recalls how her life changed virtually overnight two years ago.

She had just finished night duty as a domiciliary care assistant when she started to feel very tired and unwell.

She then developed a rash on her chest and bruising on her legs.

Concerned, she looked up her symptoms and was alarmed to discover she could have leukaemia and immediately made an appointment with at the local health centre. A doctor felt that she was being over-anxious and she was sent home with details of the Samaritans helpline but within two days she was being told in hospital she was lucky to be alive.

Clare recalls: "I had a feeling in the back of my head that things weren't right.

"The doctor obviously did not agree with my suspicions as they gave me the number for the Samaritans, a prescription for beta blockers and told me to make an appointment for the following Tuesday for blood tests. This was on a Friday and Tuesday seemed so far away.

"As I left the surgery in tears, my younger daughter Meabh's school called me to say she had fallen and hit her head. That was the last thing I needed, but thankfully she was okay.

"I described my symptoms to my boss and we thought perhaps I just needed a week off work as I was over-tired.

"My mother was helping with the girls, who were just five and nine at the time, and she was completely dumbfounded to find me having a bath at 2.30am on the Saturday morning. I had thought perhaps the heat would help with the pains I was having."

After her bath Clare did fall asleep but was stunned when she woke to discover she had lost a whole day, sleeping for 24 hours straight.

She was further alarmed on waking to discover she had blood round her mouth as her gums were bleeding and she also found a huge bruise on her thigh, which was swollen.

She rang Craigavon hospital and was advised to come to A&E where blood tests were taken.

She recalls: "A short time after arriving at the hospital I was called to the yellow area and I knew from my job that was the admissions area. My bloods came back very quickly and when both a doctor and nurse came to talk to me, I just knew it was serious."

Clare was advised to go to the City Hospital right away and on arrival was met by a consultant and nurse who admitted her immediately and broke the news that she might have leukaemia.

Clare recalls: "I cried and the first stupid question I asked was, 'Am I going to lose my hair?' My thinking was that if I lost my hair the girls would know I was really ill, so I would have to tell them the truth."

Chemotherapy treatment started immediately and Clare was told that had she waited until the following Tuesday for blood tests, she may not have been alive. The cancer was 85% through her body and she was given around 16 hours to live.

She was offered a place on a Cancer Research UK trial called AML 19, which involved 10 days of chemo, day and night, from February 4 until the end of March.

She says: "I was in hospital for six to eight weeks at a time and sometimes didn't even see the kids. That was really difficult as they were so young, but my parents Margaret and Pat were a great help."

From February to September 2018, Clare had intense chemotherapy and tests showed her bone marrow was clear.

However, there was another blow in December when further tests revealed the leukaemia was back.

"I was devastated," said Clare. "I was readmitted to hospital on January 5 last year and remained there until March 7. I was allowed out for my daughter Lily's confirmation and we had a party before I went back into hospital that night."

Clare was forced to remain in quarantine in a stem cell room while receiving full body radiation and chemotherapy injections.

She needed a stem cell transplant to save her life. Her brother Darren and sister Alison - both musicians living in America at the time - had already been tested for stem cell transplant and Alison was relieved to be a 100% match.

On April 15 of last year, Clare went through her stem cell transplant.

Two weeks later she suffered a severe reaction and her body went into toxic shock.

She recalls: "I was told it was rare to have side effects but I had them all.

"My oesophagus was burned with the radiation and I couldn't walk or talk.

"I couldn't breathe and began vomiting blood. I woke up with an ICU team at my bedside that had to literally cut my clothes off due to swelling. I apparently had put on 4st in fluid due to the toxic shock. I remember asking, 'Am I going to die?'"

It was at this point an unusual encounter in the hospital changed things. A man visiting another patient with a religious relic from the saint Padre Pio enclosed in a frame asked if he could leave it with Clare, believing it might be something that would give her strength.

She decided that if she was to survive she had to be positive.

She says: "That was on May 2 and as I held the frame I was in tears, but next morning I got up and began physio, although I wasn't able to wear either shoes or slippers after gaining 4st in fluid due to toxic shock.

"I started to eat shortly after and nobody could believe it. I was discharged on May 15."

Today she feels indebted to her family and the staff at 10 North in Belfast City Hospital for their amazing care.

"I would also like to say a special thank-you to all my cousins and close friends for their love and support throughout my journey," she says. "My sister flew home from the US to be with me for the second round of treatment but my close friends, cousins and aunt Bernadette were with me the whole time."

And after everything she has been through, she is hoping to give something back by calling on people to support Cancer Research UK's Race for Life at Home event.

Last year Race for Life participants in Northern Ireland raised 98,646 to support vital research to develop gentler and more effective treatments for cancer.

Many of the scientists and researchers funded by Cancer Research UK are currently being redeployed to help in the fight against Covid-19, including assisting with testing.

By helping to beat coronavirus, the charity can lessen the impact it is having on the care of cancer patients.

Jean Walsh, Cancer Research UK's spokesperson for Northern Ireland, said: "At a time when it feels like everything is at a standstill, there is one thing that hasn't stopped - cancer.

"Our priority as a charity is ensuring that people affected by cancer are getting the support they need right now.

"But we are already getting people asking about doing Race for Life at Home because they don't want to see the charity lose out on vital funding. It's truly humbling to see the response.

"So, from their homes, we'd love for supporters to join us and Race for Life at Home in these challenging times. From a run or 5K walk around the garden to limbo in the living room, there is no wrong way to Race for Life at Home.

"With no entry fee, people might choose to twerk, limbo, star jump, squat, skip, dance, or come up with their own novel way of taking part and share it with friends. The message is very much that 'while we might be apart, we're doing this together'. There is no wrong way to get involved and join our community."

You can visit raceforlife.org and sign up free for ideas on how to create your own Race for Life at Home challenge.

And the Cancer Research UK Race for Life Facebook page will help people feel energised with weekly live workout sessions.

Organisers are also inviting participants to join the Race for Life at Home community by sharing photos and videos on social media using the hashtag #RaceForLifeAtHome.

Cancer Research UK was able to spend over 2m last year in Belfast on some of the UK's leading scientific and clinical research.

A new date for Race for Life Belfast has been set for Wednesday, October 7.

Participants who have already signed up for a Race for Life event which is now postponed will be contacted directly by the charity. Participants will be transferred to the new date but if they can't make it there is the option to request a refund or donate the entry fee to help fund cancer research.

Visit raceforlife.org or call 0300 123 0770. Join in and share with #RaceForLifeAtHome

Belfast Telegraph

Read more:
Co Armagh mum diagnosed with leukaemia and told that she had just 16 hours to live now inspiring people to sign up and do the Race for Life at Home in...

Bone Marrow Stem Cells Comments Off on Co Armagh mum diagnosed with leukaemia and told that she had just 16 hours to live now inspiring people to sign up and do the Race for Life at Home in… | April 28th, 2020

GlobalStem Cell Therapy Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.

MarketInsightsReports has announced the addition of the Global Stem Cell Therapy Market Research Report 2020 The report focuses on global major leading players with information such as company profiles, product picture and specification.

Get Sample Copy of Stem Cell Therapy Market Report

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/inquiry?Mode=10

Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), request free sample for complete list of companies.

The leading players of industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among players will help the industry aspirants in planning their strategies.

Summary

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell Therapy market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell Therapy industry.

Stem Cell Therapy Market Segmentation by types, Applications and regions:

Market Segment by Type covers:

Autologous

Allogeneic

Market Segmented by Applications:

Musculoskeletal Disorder

Wounds & Injuries

Cornea

Cardiovascular Diseases

Others

Market Segment by Regions:

North America (the United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)

Available [emailprotected] (Exclusive new year offer Flat 20%- Use code MIR 20):

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/discount?Mode=10

These segments are thoroughly evaluated on an individual basis and a team of analysts has ensured to give a crystal clear idea about various lucrative segments of the industry. This detailed analysis using segmentation by providing precise results on industry-related markets.

The report also analyzed the evolution of industry trends. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the industry.

Frequently Asked Questions about global market:

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or 3 countries or nearly 40 analyst hours.

Note:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Visit complete report@

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026?Mode=10

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and Chinese and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More here:
Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) - Jewish Life News

Bone Marrow Stem Cells Comments Off on Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) – Jewish Life News | April 28th, 2020

Naina Mishra

Tribune News Service

Chandigarh, April 28

Fifty per cent Covid-19 cases in the city are from two affected pockets Bapu Dham Colony and Sector 30-B.

Though the street lanes from where cases are being reported are being sealed in Sector 30-B, residents have reportedly been found violating the social distancing norms by crossing roofs or playing indoor games in gatherings. This has now prompted the UT Administration to install CCTV cameras to keep a vigil on the residents in these pockets.

A total of 16 cases have been reported from Bapu Dham Colony and 14 from Sector 30-B. Manoj Parida, UT Adviser, said the outbreak needed to be contained by focusing resources at Bapu Dham Colony in Sector 26 and Sector 30-B.

CCTV cameras will be installed and drones will be used to nail those violating the norms. The police will also patrol the area regularly by donning personal protective equipment, said Parida.

MC Joint Commissioner Anil Garg said: Residents are not following social distancing and curfew orders.

Devinder Singh Babla, councillor, said: We have prepared a team of volunteers in Sector 30 and we are sealing the areas ourselves. Those found violating the norms will be penalised.

Read the original:
Give child a healthy life, not thalassaemia - The Tribune

Bone Marrow Stem Cells Comments Off on Give child a healthy life, not thalassaemia – The Tribune | April 28th, 2020

Spinal Cord Trauma Treatment Market: Global Industry Analysis 2012 2016 and Forecast 2017 2025is the recent report of Persistence Market Research that throws light on the overall market scenario during the period of eight years, i.e. 2017-2025. According to this report, Globalspinal cord trauma treatment marketis expected to witness significant growth during the forecast period.

This growth is expected to be primarily driven by increasing incidence of spinal cord trauma, and increasing government support to reduce the burden of spinal cord injuries. Additionally, development of nerve cells growth therapy is expected to boost the market in near future.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17353

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17353

The global market for spinal cord trauma treatment is is estimated to be valued at US$ 2,276.3 Mn in terms of value by the end of 2017. The global spinal cord trauma treatment market is expected to expand at a CAGR of 3.7% over the forecast period to reach a value of US$ 3,036.2 Mn by 2025end.

Global Spinal Cord Trauma Treatment Market: Trends

Global Spinal Cord Trauma Treatment Market: Forecast by End User

On the basis of end user, the global spinal cord trauma treatment market is segmented into hospitals and trauma centers. Hospitals segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period.

Hospitals and trauma centers segments are expected to approximately similar attractive index. Hospitals segment accounted for 53.2% value share in 2017 and is projected to account for 52.5% share by 2025 end.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17353

Global Spinal Cord Trauma Treatment Market: Forecast by Injury Type

On the basis of injury type, the global spinal cord trauma treatment market is segmented into complete spinal cord injuries and partial spinal cord injuries.

Partial spinal cord trauma treatment segment is expected to show better growth than the completed spinal cord treatment segment due to higher growth in the incidence rate of partial spinal cord trauma than the complete spinal cord trauma. With US$ 1,870.3 Mn market value in 2025, this segment is likely to expand at CAGR 3.8% throughout the projected period.

Global Spinal Cord Trauma Treatment Market: Forecast by Treatment Type

On the basis of treatment type, the global spinal cord trauma treatment market is segmented into corticosteroid, surgery, and spinal traction segments.

Surgery segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Surgery segment is the most attractive segment, with attractiveness index of 2.6 over the forecast period.

Global Spinal Cord Trauma Treatment Market: Forecast by Region

This market is segmented into five regions such as North America, Latin America, Europe, APAC and MEA. Asia-Pacific account for the largest market share in the global spinal cord trauma treatment market.

Large patient population due to the high rate of road accidents and crime is making the Asia Pacific region most attractive market for spinal cord trauma treatment. On the other hand, MEA and Latin America is expected to be the least attractive market for spinal cord trauma treatment, with attractiveness index of 0.3 and 0.5 respectively over the forecast period.

Read more:
Adoption of Spinal Cord Trauma Treatment Market to Increase During the COVID-19 Period on back of Increased Consumer Demand - Jewish Life News

Spinal Cord Stem Cells Comments Off on Adoption of Spinal Cord Trauma Treatment Market to Increase During the COVID-19 Period on back of Increased Consumer Demand – Jewish Life News | April 28th, 2020

MOSCOW, 28 APR RIA Novosti. A new approach to the regeneration of organs that are unrivalled in price and efficiency, has been developed by scientists at the National research University MIET. They created the material, as explained by the authors, will allow to restore the cardiac tissue after a heart attack in just 2-4 months. Data published in the journal Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.

the Experts of national research UNIVERSITY MIET for the first time in the world, according to them, managed to find a way of chemical bonding of carbon nanotubes with molecules of the most common blood protein albumin. Outdoor their physical mechanism has allowed us to develop a new method of laser 3D printing of nanocomposites.

Under the action of the laser between the albumin and carbon nanotubes there is a strong covalent bond that allows you to print the design specified shape. Living cells, e.g., connective tissue or myocardium easy root on some of the frames (scaffold), making possible the efficient recovery of damaged tissues of the body, said the head of the laboratory of biomedical nanotechnology, Institute of biomedical systems, national research UNIVERSITY MIET Alexander Gerasimenko.

As explained by scientists, they created cardiac implants is 3-4 times cheaper than Russian and 6-8 times cheaper than their foreign counterparts, outperforming both those, and others on a number of parameters. Except scaffolds used in tissue engineering, the technology is also suitable for the production of biosensors, microfluidic systems, and even advanced drugs against cancer.

We are able to print the material close to the characteristics of cardiac tissue: it can be reduced along with the myocardium and has electrical conductivity, the flowing currents of the heart. Our method also allows you to adjust the porosity of the structures, providing penetration as living cells and sprouting of capillaries and nerve endings, explained Alexander Gerasimenko.

Before implantation scaffold populated printed living cells and some time to ripen. As noted by experts of national research UNIVERSITY MIET, a number of successful experiments have shown that it can be used, including stem cells that can turn into cells of that tissue into which they are transplanted.

Scientists believe that their method will effectively deal with such pathologies as congenital heart disease and myocardial infarction, aneurysm, atherosclerosis and infarction. According to them, nano-composite patch on myocardial infarction after 2-4 months completely restores the affected area, and the frame is thus resolved.

the Scientists noted that the technology is implemented in close cooperation with leading Russian scientific centers. In the future, the team intends to proceed to introduce the method into clinical practice, and to adapt the technology for creating coatings for various implantable systems.

More here:
In Russia figured out how to cure myocardial infarction in a matter of months - The KXAN 36 News

Cardiac Stem Cells Comments Off on In Russia figured out how to cure myocardial infarction in a matter of months – The KXAN 36 News | April 28th, 2020

By Guy Adams and John Naish Apr 25, 2020

Share this article:

London - Modern science has scarcely presented a more crucial goal, offering untold riches and perhaps even a Nobel prize to the victor, as well as the chance to return the world to normal.

Yet the search for a cure for coronavirus is also uniquely perilous thanks to the dangers inherent in rushing new medical products to market.

Across the globe, thousands of researchers employed by governments, laboratories and drug firms are working flat-out to crack this all-important riddle.

As are endless armchair experts, whose numbers now evidently include Donald Trump.

Yesterday, the worlds most powerful man used a press conference to propose various highly unorthodox new treatments for coronavirus, including injecting disinfectant into the body and blasting patients with ultraviolet light.

Back in the real world, researchers are working tirelessly to combat the virus.

But while bullish claims have been made for a host of possible treatments, the truth is that scientists have little idea which ones might end up being of use.

Four months into the pandemic, we have had millions of people infected but no data yet to show that any particular treatment is especially effective, says Professor Babak Javid, the Principal Investigator at Tsinghua University school of medicine in Beijing, and a consultant in infectious diseases at Cambridge University Hospitals.

Nonetheless, here are some of the most likely candidates.

In mid-March, the American President used Twitter to amplify reports that Covid-19 patients could be successfully treated via a combination of the malaria drug hydroxychloroquine and a common antibiotic, Azithromycin.

In a later press conference, the President insisted that common sense qualified him to make such a claim, urging Americans to take it and asking them: What have you got to lose?

Well, quite a lot, as it turned out. The drugs have a catalogue of nasty side-effects, including an increased risk of cardiac arrest, skin blistering, hearing loss and an inability to move the eyes.

A study this week of 368 male coronavirus patients found that 28 per cent of those treated via hydroxychloroquine alone and 22 per cent who received both drugs (the malaria treatment and azithromycin) in U.S. hospitals died. This compares to a death rate of just 11 per cent for patients who received standard care without either drug.

Hope and hype about the drug Remdesivir have set Californian biotech firm Gileads share price soaring in recent weeks.

The medicine, which is administered via a drip, was originally developed to fight the ebola virus and works by interfering with its genetic makeup.

Although other drugs were soon found to be more effective at treating ebola, subsequent tests suggested Remdesivir had some effect on respiratory viruses such as Sars and Mers. It also appears to be relatively safe.

Gilead has so far given Remdesivir to 1,700 coronavirus patients, with dramatic effects reported in some cases. Two major studies, in the U.S. and Europe, are currently underway.

Sadly, a full-scale clinical trial in China, which has been running for longer, found no evidence it improved the fate of hospital patients, according to documents accidentally leaked this week by the World Health Organisation.

Gilead responded that these leaks contained inappropriate characterisations and insisted their findings were inconclusive.

One reason that the Chinese trials outcome was so disappointing could be that Remdesivir is likely to work best if administered early.

With Covid-19, the virus mostly replicates soon after infection, says Professor Javid. If you give the anti-viral later in the course of an illness, when a patient is hospitalised, there is not much virus left for the drug to attack.

The golden goose for pharmaceutical firms is to discover a new antibody treatment that can attach to individual particles of coronavirus and stop them wreaking havoc.

Two US drug companies, Amgen and Adaptive, recently announced a partnership to study recovered Covid-19 patients in an effort to identify and manufacture crucial virus-killing antibodies.

Another firm, Regeneron, has been conducting a study using the viruss genetic material in mice. Dozens of other companies are pursuing similar projects.

Although an antibody strategy was used against ebola, most new drugs take more than five years to develop, thanks among other things to rigorous testing designed to ensure they do not have dangerous side-effects.

This fashionable, if highly experimental, field involves harvesting blood from people who have recently recovered from coronavirus and donating it to patients who are still suffering from the disease.

Because blood plasma contains antibodies that have learned how to detect and destroy the virus, the theory is that a transfusion will kick-start the recipients ability to fight it.

Its quite easy to harvest plasma from surviving patients, says Professor Javid. It was done even during the Spanish Flu epidemic of 1918-19.

About 600 patients in America have already received this treatment. The NHS is also said to be preparing to carry out an extensive trial in the UK.

However, some experts have pointed out that many Covid-19 victims die because of an overactive immune response to the virus, causing inflammation of lungs and other vital organs. These experts worry that boosting a patients immunity via plasma therapy could actually worsen their condition.

Another problem with plasma therapy is the old-fashioned issue of supply and demand. A limited number of recovered patients are prepared to give blood, and only a finite amount can be taken from them.

However, technology now exists to manufacture synthetic antibodies using the blood of Covid-19 survivors.

Such monoclonal antibodies have become the standard treatment for ebola. Several laboratories have identified monoclonal antibodies that can apparently inhibit coronavirus in test-tubes.

Professor Javid warns, however: No one has yet worked out which of the promising monoclonal antibodies work best for Covid-19, or what might be the best way to use them in combination. This is why they are not in production yet for Covid-19.

Contracting HIV was once a virtual death sentence, but after decades of research, its now mostly a highly manageable condition thanks to a raft of well-tolerated drugs.

Indeed, many HIV drugs are now being touted as possible treatments for coronavirus, including Lopinavir and Ritonavir.

These are being trialled on coronavirus patients in studies at the Universities of Oxford and Nebraska.

But so far there is little evidence of them working outside of a laboratory setting.

The so-called master cells that develop into blood, brain, bones and organs have been touted as the basis for cures for cancer, heart disease and arthritis for years.

Little wonder, then, that the pioneering field of stem cell therapy is now being targeted at coronavirus. Among firms exploring this modish area are Mesoblast, whose boffins are testing bone-marrow cells to establish whether they can help patients develop immunity to the virus. In Wuhan, meanwhile, doctor Dongcheng Wu last month claimed hed treated nine patients by injecting umbilical stem cells. He said they all made a complete recovery within days. The success has not yet been convincingly replicated, however. Stem cell treatments are often risky, too when trialled on Parkinsons, they caused brain tumours.

Around half the patients who die with coronavirus suffer a so-called cytokine storm, in which their immune system goes into overdrive, causing, among other things, acute lung inflammation that stops them from taking on enough oxygen. With this in mind, many products designed to combat inflammation are now being trialled on Covid patients.

They include Tocilizumab, used to treat rheumatoid arthritis, and Dexamethasone, a steroid used against asthma.

The World Health Organisations Solidarity trial is meanwhile testing interferon-beta, which is used to treat multiple sclerosis.

Professor Javid believes immune drugs should be accompanied by effective antiviral treatment: We know from treating flu patients suffering cytokine storms that if you dampen their immune response without also giving them an antiviral drug, it can reduce the patients virus-fighting defences and allow the virus to run wild.

These are the cholesterol-lowering drugs prescribed to millions at risk of heart disease. Now scientists wonder if statins should be given to patients with severe Covid-19 symptoms, for two reasons.

Harvard University investigators recommend their use because they have anti-inflammatory powers.

Scientists added last month in the journal Drug Development and Research that statins have also shown an ability to moderate the immune system and thus protect patients lungs from cytokine storm damage.

Professor Jon Cohen, emeritus professor of infectious diseases at Brighton and Sussex Medical School, argues that while statins have shown potential in test-tube trials, in living patients they have only really shown benefits for the cardiovascular system.

In normal circumstances viruses develop a key that enables them to pick a cells locks and break in, hijacking the cells machinery to make more copies of the virus. Peptide inhibitors stick to this key, rendering it unable to do its job.

We already know that Covid-19 invades human cells through a protein receptor, ACE2.

The big question, therefore, is: what might block the coronavirus attaching to the ACE2 receptor?

Chemists at Illinois University used high-powered computers to identify the amino-acid chemicals in the ACE2 receptor that the virus targets. They then constructed a drug with amino-acids that should stick to the viruss key, rendering it useless.

But as the scientists acknowledge in journal ACS Nano this month, they have tested their chemical in computer simulations not in the lab and certainly not on humans. A lot of hurdles lie ahead.

Ultimately, most scientists agree that coronavirus prevention a vaccine is better than any treatment or cure.

Thats why governments are throwing the proverbial kitchen sink at efforts to create one, with more than 140 projects currently running in parallel all over the world.

Everyone expects a vaccine to appear in the end. But much hinges on how quickly that happens.

Thats why there was so much excitement this week when it emerged that scientists at Oxford University have already begun to conduct their first human vaccine tests.

Other clinical trials in humans are already underway in China.

Nevertheless, Professor Chris Whitty, Englands Chief Medical Officer, says the chance of a vaccine becoming available in the next calendar year are incredibly small.

Why? Because we can move only as quickly as extreme caution will allow, says inoculation expert Dr Kai Hu of Imperial College. He reports Imperials lab has already created a harmless pseudo-virus that carries a coronavirus protein. But, he stresses: Safety is our number one priority. We dont yet know how toxic the vaccine would be to humans.

Given Covid-19s devastating infectiousness, the world will have to keep its fingers crossed that the dash for an effective jab proves a success rather than inadvertently plunging humanity into further peril.

Three members of the same family are taking part in a groundbreaking coronavirus vaccine trial. Mum Katie, dad Tony and daughter Rhiannon Vinney are among more than 1,000 participants taking part in the Oxford University trials.

Teaching assistant Katie, 46, saw the plea for healthy volunteers and urged her husband, 53, who runs two pubs, and their 18-year-old student daughter to sign up with her.

The mum-of-four, from Oxford, said she was not worried about health risks from taking part, because she believes the team have done everything they could to make it safe.

She added: I just want to help so life can return to normal. You have to live in a cave not to know somebody who is affected by this. I really do hope this is the cure.

Read this article:
Will the race for a Covid-19 cure end in triumph or tragedy? - IOL

Cardiac Stem Cells Comments Off on Will the race for a Covid-19 cure end in triumph or tragedy? – IOL | April 28th, 2020

Although I live in New York City, many of my friends call Seoul, South Korea, home. Through our many FaceTimes, KakaoTalk messages, and visits, they've introduced me to trendy Korean beauty brands that haven't made their way to America yet, like Hince, Sioris, and Nonfiction. They also share their picks from K-beauty brands we know and love in the U.S., such as Sulwhasoo, Dr. Jart, and Nature Republic. Every time I hear about their favorite products, I'm fascinated by how different they are from our stateside K-beauty offerings.

We're only exposed to a fraction of what is available on the other side of the world, and we are missing out on dreamy lip tints, barely-there cushion foundations, and magical moisturizers. With this in mind, I put my friends' makeup, hair, and skin-care selections in one place.

Some background on the names I'm about to mention: Daniella is my clean beauty expert. Whenever I see her, she always gives me a bag full of goodies made with natural, cruelty-free ingredients. When I want to know about the hottest brands at the moment, I go to Haylie. Joyce, founder of consulting agency Talk to Her, always has her eye out for the latest K-beauty innovations. Tattoo artist Young, on the other hand, mixes classic imports, like SK-II and Urban Decay, with unexpected K-beauty finds.

Consider this a list of K-beauty products Koreans actually use.

All products featured on Allure are independently selected by our editors. However, when you buy something through our retail links, we may earn an affiliate commission.

See the rest here:
23 Best Korean Beauty Products, According to Koreans Hair, Makeup, Skin-Care Reviews - Allure Magazine

Skin Stem Cells Comments Off on 23 Best Korean Beauty Products, According to Koreans Hair, Makeup, Skin-Care Reviews – Allure Magazine | April 28th, 2020

By Sarah Parsons 28-Apr-2020

Hair Care | Ingredients | Skin Care

The Swiss-led speciality chemicals manufacturer Clariant Active Ingredients has developed two new plant-based ingredients

Speciality chemicals giant Clariant has unveiled its latest beauty ingredients.

This week, the Swiss-led company launched two new plant-based ingredients for skin and hair.

Clariant Active Ingredients, Clariant's beauty business unit, released Rootness Energize, an extract of Luffa cylindrica, otherwise known as Egyptian cucumber, and can also be used as a natural cleaning sponge.

Developed for the skin, Claraint claims that sustainably-sourced Rootness Energize is rich in bryonolic acid, and can increase energy production in skin cells and stimulate ATP production.

"In turn, Rootness Energize visibly increases skin elasticity and reduces age-related lack of tonicity and firmness appealing factors for products such as firming creams, skin elasticity boosters and revitalising care products for well-aging skin care," explained the company.

Reported visible results include more than a 20% increase in firmness, tonicity and elasticity with 1% Rootness Energize.

For the hair, Clariant Active Ingredients has developed EquiScalp to target tightness, extreme dryness, itchiness and redness.

Based on stem cells from the Central Asian Malus domestica apple tree, according to the firm, the ingredient protects the scalp as it maintains the level of healthy bacteria.

Malus domestica is said to contain concentrated phloridzin, which can control inflammation as well as sebum overproduction.

Clariant Active Ingredients recommends EquiScalp for oily scalp treatments, sensitive scalp formulas and scalp itch erasers.

Alexandre Lapeyre, Global Head of Marketing, Clariant Active Ingredients, described EquiScalp and Rootness Energize as examples of using technology to develop sustainable ingredients.

"We apply science to nature to create potent actives effective at addressing very specific beauty needs, each one underpinned by plant resources preservation, traceability, no exploitation of cultural land and ecological cultivation," Lapeyre said.

"In doing so, we help cosmetic formulators support consumers requests for scientifically-proven and sustainably-sourced plant derived ingredients.

Like this story? For the latest in ingredients, formulation, packaging and regulation subscribe to SPC Magazine, for more information click here.

The rest is here:
Clariant taps natural sponges and apple trees for new beauty ingredients - Cosmetics Business

Skin Stem Cells Comments Off on Clariant taps natural sponges and apple trees for new beauty ingredients – Cosmetics Business | April 28th, 2020

Mathais Fleury, Givaudans global category manager of biotech actives, told CosmeticsDesign-Asia that leveraging on green biotechnology would allow companies to find solutions to consumers desire for products that are natural, sustainable and high-performing.

Green Biotech truly is a key pillar of the future. Consumers are looking for more naturality while protecting nature a difficult challenge, made possible by biotech along with a high level of innovation, said Fleury.

Most recently, the Swiss company collaborated with South Korean biotech company BIO-FD&C to tackle two frustrating beauty concerns by leveraging on green biotechnology.

It recently unveiled two actives, K-phyto [SC] Camellia and K-phyto [PP] GHK, which were developed to address dry scalp and oily skin respectively.

This exclusive partnership with Bio FD&C leverages the untapped power of plants through stem cell cultures and unique phytopeptides. It allows our experts to offer innovative natural and reliable solutions for hair and skin care issues such as dry scalp and oily skin, while protecting our planet, said Fleury.

K-phyto [SC] Camellia is an ingredient obtained from camellia phytoplacenta cells culture.

According to the company, the active can increase the scalp moisture content by 13.8%. This reinforces the epidermal cohesion of the scalp keratinocytes and reduces dry flakes and dandruff down by 33.6%.

It also was observed soothe the scalp by being able to reduce erythema down 6.6%.

According to Givaudan, having botanical claims with popular ingredients such as camellia, more commonly known as Tsubaki in the region, can drive hair care product launches by 70% in APAC.

The second ingredient, K-phyto [PP] GHK, is a molecule that combines botanicals and peptides to act on the mechanisms of sebum production.

Clinical studies have shown facial sebum production reduction by 35.5% in two weeks and 67.5% in one month.

Oily skin is a major claim requested by the market, specifically in APAC. Clinical results with the phytopeptide we've chosen to bring to market are outstanding and we definitely believe this could be a game changer, said Fluery.

The Swiss firm believes that the two actives showed a lot of promise for the global market.

Our partner was already doing a very good job in its local market, but we want to leverage our access to different places over the world to highlight its expertise and know-how. This collaboration is a real opportunity to bring innovative ingredients to consumers globally, and that's why we'll offer these products to our partners all over the world, said Fleury.

Additionally, these ingredients are aligned with the ideals of clean beauty, one of the most talked-about trends in the beauty market right now.

The two technologies that we've identified in Bio FD&C portfolio are a perfect answer to this need of clean beauty combined with performance, said Fluery.

More here:
'A key pillar of the future': Givaudan tips growth for ingredients developed with green biotech - CosmeticsDesign-Asia.com

Skin Stem Cells Comments Off on ‘A key pillar of the future’: Givaudan tips growth for ingredients developed with green biotech – CosmeticsDesign-Asia.com | April 28th, 2020

CRANFORD, N.J., April 27, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc.. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.

The cells, called NoveCite Cells or NC-MSCs, are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. NC-MSCs are mesenchymal stem cells derived from a single donor's fibroblasts that have been dedifferentiated into an induced pluripotent stem cell (iPSC) master cell bank, thereby avoiding the need to source additional donor cells. The iPSCs are then further differentiated into a mesenchymal stem cell (MSC) therapy. Citius and Novellus plan to develop NC-MSCs for the treatment of ARDS, and last month the companies signed an exclusive option agreement.

The Company plans a multi-center randomized placebo-controlled dose-finding study followed by an expansion phase to assess the safety, tolerability, and efficacy of NC-MSCs in patients with moderate to severe ARDS due to COVID-19. The proposed trial, a Phase 1b/2 clinical trial, is titled "A Randomized Placebo-Controlled Dose-Finding Study Followed by a Dose Level Expansion to Assess the Safety and Efficacy of NoveCite MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to SARS-CoV-2 Disease (COVID-19)," or "MARCO". The primary objectives of this study are to evaluate the safety and efficacy of NoveCite cells as a treatment for subjects with moderate-to-severe ARDS due to COVID-19 and to identify therapeutic doses.

"MSCs have an established track-record of clinical safety, and have shown promise in the treatment of inflammatory lung disease," said Matt Angel, PhD, co-founder and Chief Science Officer at Novellus, Inc. "Our research has shown that the NoveCite cells, being derived from mRNA-reprogrammed iPSCs, secrete higher levels of immunomodulatory proteins than donor-derived MSCs, and have unique manufacturing advantages."

"We believe we have the key elements in place from a clinical design and manufacturing point of view to evaluate this novel cell therapy approach to deal with the current pandemic," said Myron Holubiak, Chief Executive Officer of Citius. "ARDS is a very serious complication for many patients suffering from COVID-19, and is believed to account for about 80% of the deaths in ventilated patients. There is no proven or FDA-approved treatment for it, other than oxygen therapy, including use of mechanical ventilation, and fluid management. Literature from previous investigational studies with MSCs in the treatment of lung injuries support the idea that MSCs could prove effective in treating COVID-19-related ARDS. We look forward to our FDA discussions and are excited to be at the cusp of what could be a novel and effective therapy for ARDS."

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 will benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Inc.Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its non-immunogenic mRNA, nucleic-acid delivery, gene editing, and cell reprogramming technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

Safe HarborThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement with Novellus within the option period; our need for substantial additional funds; the ability to access the FDA's CTAP program for the MARCO trial; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks associated with conducting trials for our product candidates, including those expected to be required for any treatment for ARDS and our Phase III trial for Mino-Lok; risks relating to the results of research and development activities; risks associated with developing our product candidates, including any licensed from Novellus, including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; uncertainties relating to preclinical and clinical testing; the early stage of products under development; risks related to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-announces-pre-ind-submission-to-fda-under-the-coronavirus-treatment-acceleration-program-for-a-novel-stem-cell-therapy-for-acute-respiratory-distress-syndrome-ards-in-covid-19-301047150.html

SOURCE Citius Pharmaceuticals, Inc.

Continue reading here:
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory...

Skin Stem Cells Comments Off on Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory… | April 27th, 2020

Stem Cell Restore is a formula that works toward improving your health on a cellular level to decrease age-related weakness and fatigue. This product employs natural ingredients for reaching its goals such as resveratrol, black current cocktail, icariin, and grape seed.

Multiple research works from renowned universities back the approach that this product takes. The best part is that it makes you feel stronger, younger, more refreshed, and more energetic without requiring you to get injected with needles. A simple and convenient solution. Another anti-aging plus weight loss supplement that you can opt for is Resurge. This is a new formula by John Barban. Interested folks can learn more about Resurge customer reviews on USAToday.

Stem Cell Restore Review

Aging is the only thing in your life that is bound to happen. Unfortunately, it is not the best experience. Sure, it gives you wisdom, but those wrinkles, that weakness, declining energy levels all these negative factors completely loot the good things. After all, no one likes to wake up in the morning to feel down and weak. No one likes it when it their joints ache or when they look in the mirror to see a dull reflection.

This brings us to possible solutions that you can go for. One of these is Stem Cell Restore. This is a potent dietary supplement that has been made using natural ingredients. The product is backed by science which is what marks it as reliable. Since it comes in the form of capsules, it can be a convenient addition to your routine. Hence, if you are on the lookout for an age-reversing formula, this is one that you can invest in.

Why Choose This Product?

Around the globe, women and men alike are waiting for a magical solution for saving themselves from accelerated aging. There certainly are many options available out there. However, most of these are not worth it. Why? Because they come with negative side effects. Not to mention, these so-called techniques for erasing the effects of aging are all supremely painful. They involve countless injections or an elaborate surgery.

Would you like to still go for these youth preserving tactics? Surely, youre at the very least hesitant. If you decide to go ahead nevertheless, know that the procedures are expensive. They cost hundreds of dollars and still, they are unnatural and eventually make your skin sag. This is where Stem Cell Restore comes into the picture and steals the limelight. The dietary supplement is based on the concept of stem cell surgery.

However, it has three favorable points that win over any surgery. First of all, it doesnt cost as much. In fact, you get to become youthful, energetic, and strong all with a solution that is less than $100. Secondly, the product happens to be completely natural. It doesnt contain any harmful components such as chemicals, additives, preservatives, and the like. This translates to safe usage. Lastly, theres no needles involved; you are just supposed to take the pills regularly.

Working Of This Product

Stem Cell Restore taps into the idea of repairing cells and rejuvenating them. By doing so, it is able to refresh your health completely. All your parts from tendons and joints to your heart and kidneys are able to function better as a result. Old cells are repaired at a fast rate and new ones are created. This makes you feel fresher, and more active. Its not uncommon of people to experience bodily aches and fatigue after crossing 30 years of age.

This product is a suitable solution for everyone. It gets to the core of preserving youth and improves health. Moreover, it also tackles the issue of inflammation which is what disturbs health in numerous ways. Unlike mainstream products, your skin is not the only organ that benefits. In fact, your entire body experiences the effects. To reach its goals, the formula employs only natural ingredients which are effective at their job. As mentioned above, Resurge is another formula for deep sleep and anti-aging. It comes with a money-back guarantee. You can check out more Resurge reviews on Yahoo Finance before deciding which one to buy among the two.

Ingredients Of This Product

Stem Cell Restore has an entirely natural composition. It doesnt comprise of any such ingredients which can have damaging effects in the short- or long-run. The product is a winner mainly because of this. No additives, fillers or other such harmful components are present in the formula. Since all the ingredients are completely organic you dont have to worry about any negative side effects of use. Lets take a look at the ingredients:

Pricing Of The Product

Did you know that you can get this product for absolutely free? Yes, thats true. For a trial period, the dietary supplement is entirely free of cost. You just have to pay for shipping and handling which just requires $9.95 from your wallet. The trail period lasts for 30 days.

If the product satisfies you, its yours and automatically charges are deducted from your account or card. Thats simple and gives you a chance to see whether or not this supplement actually works. There are also three bonus products that tag along with this supplement. These come for free as well. Heres a list of the bonus product that accompany:

Verdict

Stem Cell Restore is a great product for maintaining youthful energy and strength. The product is great for recovering from the pain and fatigue that usually occurs after the age of 30. This formula repairs and encourages the production of cells through the body. In this way, it improves each organs functionality and hence, overall health. You can know more about this dietary supplement by visiting its website online.

Related

Read more from the original source:
Stem Cell Restore Helps Regain Youthful Strength And Energy - ZOBUZ - Zobuz

Skin Stem Cells Comments Off on Stem Cell Restore Helps Regain Youthful Strength And Energy – ZOBUZ – Zobuz | April 27th, 2020

As the number of confirmed cases of COVID-19 surges past 2.5 million globally with deaths at 177,115 (as of April 22), clinicians and pathologists are struggling to understand the damage its wrought. They realize that although the lungs are ground zero, its reach can extend to many organs: Its viciousness is breathtaking and humbling.

When an infected person expels virus-laden droplets and someone else inhales them, this coronavirus enters the nose and throat. It finds a welcome home in the lining inside the nose. Cells there are rich in a surface receptor (pandikit) called angiotensin-converting enzyme 2 (ACE2), which the virus requires to enter the cell. Once inside, the virus hijacks the cells reproductive machinery, making myriad copies of itself and invading new cells.

A virus can copy anything it wants and can even make itself comfortably adapt to the environment where it chooses to stay while killing the normal cells of your body.

As it multiplies, an infected person may shed copious amounts of it, especially during the first week or so. Symptoms may be absent or the infected may develop fever, dry cough, sore throat, loss of smell and taste, or head and body aches.

Photo from dermatologyadvisor.com

If the immune system does not fight back, the virus then marches down the windpipe to attack the lungs, where it can turn deadly. This is because the thinner, distant branches of the lungs respiratory tree end in tiny air sacs called alveoli, which are also rich in ACE2 receptors. The virus can attach itself again and wreak havoc.

Normally, oxygen crosses the air sacs into the capillaries, tiny blood vessels that lie beside them. The oxygen is then carried to the rest of the body. COVID infection disrupts this healthy oxygen transfer. The front liners of our immune system, white blood cells, release inflammatory molecules called chemokines that summon more immune cells to target and kill virus-infected cells, leaving a stew of fluid and dead cells pus behind. This results in pneumonia: coughing, fever and rapid, shallow breathing.

Some COVID-19 patients recover, sometimes with no support other than oxygen. But others deteriorate, often suddenly, developing a condition called acute respiratory distress syndrome (ARDS). The oxygen levels in their blood plummet and they struggle even harder to breathe. On X-rays and computed tomography scans, their lungs are riddled with white opacities (areas without air). Commonly, these patients end up on ventilators. Many die. Autopsies show their alveoli became stuffed with fluid, white blood cells, mucus and the detritus of destroyed lung cells.

The invaders impact does not end there. The bodys response to destroy it can injure even more organs. Clinicians suspect that the driving force in many gravely ill patients downhill trajectories is a disastrous overreaction of the immune system, or cytokine storm.

Cytokines are chemical signaling molecules that guide a healthy immune response, but in a cytokine storm, levels of certain cytokines soar far beyond whats needed, and immune cells start to attack healthy tissues. Blood vessels leak, blood pressure drops, clots form and catastrophic organ failure can ensue.

Cardiovascular damage occurs.Kidneys, liver, blood vessels, the skin and brain are affected as well.Blood clots can break apart and land in the lungs, blocking vital arteries a condition known as pulmonary embolism that can kill COVID-19 patients.

Brain incursion via the nose can reach the olfactory bulb, inducing loss of smell. Clots from arteries can also lodge in the brain, causing a stroke.

Some people with COVID-19 briefly lose consciousness. Doctors wonder whether in some cases, infection depresses the brain stem reflex that senses oxygen starvation, which explains why some patients are not gasping for air, despite dangerously low blood oxygen levels.

COVID-19 can also infect the lining of the lower digestive tract, where ACE2 receptors are abundant. Viral RNA has been found in as many as 53 percent of patients stool samples, raising the unsettling possibility that it could be passed on through feces. As of this writing, theres no evidence that fecal transmission can occur.

Others develop conjunctivitis pink, watery eyes, others had elevated levels of enzymes indicating injury to the liver or bile ducts.But this may also be due to drugs or an over-driven immune system.

Lastly, cutaneous or skin manifestations have been reported in COVID-19 patients:

Generalized sporadic red rasherupting along the trunk or extremities that are typically transient and resolve on their own. They may be very itchy. Sometimes this can be confused with dengue.

Petechiae.Pinpoint bleeding underneath the skin that does not disappear when pressure is applied.

Generalized urticaria are wheal-like rashes that can coalesce together to form large plaques.

Vesicular eruptionmimicking varicella (chicken pox) blisters.

Vasculopathic presentations. Frostbite-like lesions on the feet and hands multifocal, often asymmetric patches manifest in two to three days. It then evolves to the formation of blisters, to bruises or necrosis (black, dead skin).Sometimes they appear as red, purplish bumps on the feet and hands that evolve into hemorrhagic bullae, or develop a blackish crust due to damage to the lining of the blood vessels, leading to clots that block blood vessels. These can lead to ulcer or gangrene formation, and death.

Acute hemorrhagic edema in infants.Sudden swelling of limbs with patches of bruises in a well-appearing child, before the rash dissipates in 48 hours along with the swelling.

Erythematouslarge patches scattered all over the body that may be slightly itchy.

Localized extreme pruritus,like in the wrist or ankle areas only.

This map of the devastation that COVID-19 can inflict on the body is still just a sketch. It will take years of painstaking research to sharpen the picture of its reach.

* * *

For inquiries, call 8401-8411 or 0917-497-6261, 0999-883-4802 or email gc_beltran@yahoo.com. Follow me on facebook@dragracebeltran.

Continued here:
COVIDs devastation on the body includes the skin - Philippine Star

Skin Stem Cells Comments Off on COVIDs devastation on the body includes the skin – Philippine Star | April 27th, 2020

Cosmetic Skin CareMarketBusiness Insights and Updates:

The latest Marketreport by a Data Bridge Market Researchwith the title[Global Cosmetic Skin CareMarket Industry Trends and Forecast to 2026].The new report on the worldwide Cosmetic Skin CareMarketis committed to fulfilling the necessities of the clients by giving them thorough insights into the Market. The various providers involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.The reports provide Insightful information to the clients enhancing their basic leadership capacity identified.Exclusive information offered in this report is collected by analysis and trade consultants.

Global cosmetic skin care market is set to witness a substantial CAGR of 5.5% in the forecast period of 2019- 2026.

Cosmetic skin care is a variety of products which are used to improve the skins appearance and alleviate skin conditions. It consists different products such as anti- aging cosmetic products, sensitive skin care products, anti- scar solution products, warts removal products, infant skin care products and other. They contain various ingredients which are beneficial for the skin such as phytochemicals, vitamins, essential oils, and other. Their main function is to make the skin healthy and repair the skin damages.Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cosmetic-skin-care-market

Thestudy considers the Cosmetic Skin CareMarketvalue and volume generated from the sales of the following segments:Major Marketmanufacturerscovered in the Cosmetic Skin CareMarketare:LOral, Unilever, New Avon Company, Este Lauder Companies, Espa, Kao Corporation, Johnson & Johnson Services, Inc., Procter & Gamble, Beiersdorf, THE BODY SHOP INTERNATIONAL LIMITED, Shiseido Co.,Ltd., Coty Inc., Bo International, A One Cosmetics Products, Lancme, Clinique Laboratories, llc., Galderma Laboratories, L.P., AVON Beauty Products India Pvt Ltd, Nutriglow Cosmetics Pvt. Ltd, Shree Cosmetics Ltd

By Product

By Application

By Gender

By Distribution Channel

Get Table of Contents with Charts, Figures & Tables @https://www.databridgemarketresearch.com/toc/?dbmr=global-cosmetic-skin-care-market

Based on regions, the Cosmetic Skin CareMarketis classified into North America, Europe, Asia- Pacific, Middle East & Africa, and Latin AmericaMiddle East and Africa (GCC Countries and Egypt)North America (United States, Mexico, and Canada)South America(Brazil, Argentina etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Market Drivers:

Market Restraints:

Key Developments in the Market:

Key Benefits for Cosmetic Skin CareMarket:

Enquire Here For Discount Or Cosmetic Skin CareMarket Report Customization@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cosmetic-skin-care-market

About Us:Data Bridge Marketresearch endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process Data Bridge set forth itself as an unconventional and neoteric Marketresearch and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Marketopportunities and foster efficient information for your business to thrive in the Market.We ponder into the heterogeneous Markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the Markettrends. Data Bridge delves into the Markets across Asia, North America, South America, Africa to name few.

Contact Us:Data Bridge MarketResearchUS: +1-888-387-2818

Read the original here:
Cosmetic Skin Care Market to see impressive Growth by 2027| Leading Companies- L'Oral, Unilever, Espa, Kao, Johnson & Johnson - Cole of Duty

Skin Stem Cells Comments Off on Cosmetic Skin Care Market to see impressive Growth by 2027| Leading Companies- L’Oral, Unilever, Espa, Kao, Johnson & Johnson – Cole of Duty | April 27th, 2020

(L-R) Professor Geoff Lindeman and Professor Jane Visvader

are joint heads of the Institutes ACRF Stem Cells and Cancer

Division.

Using advanced three-dimensional (3D) imaging techniques, the team observed how the immune cells monitor for threats in the mammary ducts and help to maintain tissue health by eating up dying milk-producing cells needing to be cleared away once lactation stops.

The preclinical research was led by Walter and Eliza Hall Institute researchers Dr Caleb Dawson, Professor Geoff Lindeman and Professor Jane Visvader, along with Dr Anne Rios who is now based at the Princess Mxima Center for Pediatric Oncology, Netherlands. It was published today in the journal Nature Cell Biology.

Institute breast cancer researcher Dr Caleb Dawson.

The mammary gland is a dynamic organ that undergoes dramatic remodelling throughout life. The branching ducts bloom to form milk-producing factories in lactation, which must be eliminated once lactation stops. Mammary ducts are of particular interest to breast cancer researchers because this site is prone to cancer development.

While exploring mammary ducts using high-resolution imaging techniques, Dr Dawson said the researchers were surprised to discover a new immune cell type, and its specific role in maintaining healthy, intact breast tissue.

We discovered an entirely new population of specialised immune cells, which we named ductal macrophages, squeezed in between two layers of the mammary duct wall.

We were excited to find that these cells play an essential role at a pivotal point in mammary gland function called involution when lactation stops, milk-producing cells die and breast tissue needs to remodel back to its original state, he said.

We watched incredulously as the star-shaped ductal macrophages probed with their arms and ate away at dying cells. The clearing action performed by ductal macrophages helps redundant milk-producing structures to collapse, allowing them to successfully return to a resting state, Dr Dawson said.

When the researchers later removed ductal macrophages from the mammary ducts they discovered that no other immune cells were able to swiftly carry out this essential process.

Most organs in the body including the brain, liver, lung, skin and intestine have their own population of macrophages a name of Greek origin that means big eater. These cells play important roles in regulating infection, inflammation and organ function within their sites of residence.

Professor Visvader said discovering mammary duct-specific macrophages was a remarkable step forward in understanding how the immune system interacted with the ductal network and impacted upon mammary gland development.

As breast cancer researchers, there is a need to understand which cells are doing what, so that we can identify how these intricate cellular processes become dysregulated, such as in the case of breast cancers, she said.

More than 19,000 Australians are diagnosed with breast cancer every year. It is the most common cancer in Australian women.

Dr Dawson said that going forward, the team hoped to explore the function of ductal macrophages at different stages of mammary gland development, such as the transitions into adulthood and pregnancy.

We also want investigate the role that these duct-specific immune cells play in helping cancer to grow and spread.

Ductal macrophages are spread throughout the mammary ducts. As cancer grows, these macrophages also increase in number. We suspect that theres the potential for ductal macrophages to inadvertently dampen the bodys immune response, which would have dangerous implications for the growth and spread of cancer in these already prone sites, Dr Dawson said.

Professor Visvader said the teams ultimate goal was to understand these cells enough to manipulate them.

Given that tumour macrophages likely promote growth of the tumour, blocking their activity could serve as a treatment strategy for breast cancer, she said.

The research was supported by the National Health and Medical Research Council, the National Breast Cancer Foundation, the Australian Cancer Research Foundation, The Qualtrough Cancer Research Fund, Cure Cancer Australia and the Victorian Government.

Read more:
New type of immune cell discovered in breast ducts - Mirage News

Skin Stem Cells Comments Off on New type of immune cell discovered in breast ducts – Mirage News | April 27th, 2020

Astrocytes play a direct role in the regulation of neuronal circuits involved in learning and memory, according to new research from Baylor College of Medicine and M.D. Anderson Cancer Center.

Huang et al reveal region-specific transcriptional dependencies for astrocytes and identify astrocytic NFIA as a key transcriptional regulator of hippocampal circuits. Image credit: Huang et al, doi: 10.1016/j.neuron.2020.03.025.

Astrocytes are star-shaped glial cells in the brain and spinal cord.

They have unique cellular, molecular and functional properties and outnumber neurons by over fivefold. They occupy distinct brain regions, indicating regional specialization.

There is evidence suggesting that transcription factors proteins involved in controlling gene expression regulate astrocyte diversity.

A team led by Professor Benjamin Deneen from Baylor College of Medicine looked to get a better understanding of the role transcription factor NFIA, a known regulator of astrocyte development, played in adult mouse brain functions.

The researchers worked with a mouse model they had genetically engineered to lack the NFIA gene specifically in adult astrocytes in the entire brain.

They analyzed several brain regions, looking for alterations in astrocyte morphology, physiology and gene expression signatures.

We found that NFIA-deficient astrocytes presented defective shapes and altered functions, Professor Deneen said.

Surprisingly, although the NFIA gene was eliminated in all brain regions, only the astrocytes in the hippocampus were severely altered. Other regions, such as the cortex and the brain stem, were not affected.

Astrocytes in the hippocampus also had less calcium activity calcium is an indicator of astrocyte function as well as a reduced ability to detect neurotransmitters released from neurons.

NFIA-deficient astrocytes also were not as closely associated with neurons as normal astrocytes.

Importantly, all these morphological and functional alterations were linked to defects in the animals ability to learn and remember, providing the first evidence that astrocytes are to some extent controlling the neuronal circuits that mediate learning and memory.

Astrocytes in the brain are physically close to and communicate with neurons. Neurons release molecules that astrocytes can detect and respond to, Professor Deneen said.

We propose that NFIA-deficient astrocytes are not able to listen to neurons as well as normal astrocytes, and, therefore, they cannot respond appropriately by providing the support needed for efficient memory circuit function and neuronal transmission. Consequently, the circuit is disrupted, leading to impaired learning and memory.

The findings were published online in the journal Neuron.

_____

Anna Yu-Szu Huang et al. Region-Specific Transcriptional Control of Astrocyte Function Oversees Local Circuit Activities. Neuron, published online April 21, 2020; doi: 10.1016/j.neuron.2020.03.025

View post:
Study Reveals New Role of Astrocytes in Brain Function | Neuroscience - Sci-News.com

Spinal Cord Stem Cells Comments Off on Study Reveals New Role of Astrocytes in Brain Function | Neuroscience – Sci-News.com | April 27th, 2020

Advancing your induced pluripotent stem cells or human embryonic stem cell therapy research to clinical applications requires careful material selection because the quality of starting materials significantly impact the properties of your final stem cell therapy product. Gibco CTS products have been developed to ease the transition from stem cell therapy research to clinical applications by providing high quality GMP manufactured, commercial scale ancillary materials with a high degree of qualification, traceability and regulatory documentation. In an effort to help you maximize the potential of your stem cell research and therapy, and simplify the transition to clinic-ready processes, we offer an extensive selection of research use stem cell research products with complementary CTS formulations. Our CTS products are used in commercially approved cell therapies as well as over 100 clinical trials and are backed by our professional regulatory support and over 30 years of GMP manufacturing experience.

Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) , sometimes collectively referred to as pluripotent stem cells (PSCs), are cells that have the ability to renew themselves indefinitely and differentiate into almost any cell type when exposed to the right microenvironment. These unique properties enable the application of induced pluripotent stem cells and embryonic stem cells in disease modeling, drug discovery, drug toxicity testing, and cell therapy. Strikingly, most embryonic stem cell and induced pluripotent stem cell applications have the potential to improve human health, none more directly so than ESC or iPSC therapy. The most intuitive approach for ES or iPS cell therapy is to transplant PSC-derived cells for the direct replacement of damaged or degenerated cells or tissue. However, there are many other approaches to ES or iPS stem cell therapy such as transplanting PSC-derived cells that then release signals triggering endogenous repair mechanisms.

At Thermo Fisher Scientific, we support the development of your human embryonic stem cell therapy or induced pluripotent stem cell therapy from the earliest stages of research and all the way to the clinic. We offer high-quality products across the iPS cell therapy workflow from reprogramming to differentiation. Most Gibco media and supplements for culture and differentiation are manufactured under GMP conditions at sites that use methods and controls that conform to current Good Manufacturing Practices (cGMP) for medical devices. These manufacturing sites are ISO 13485 and ISO 9001certified, and the rigorous practices we adhere to at these sites help ensure the consistency, reliability, and high quality of a wide variety of iPSC therapy workflow reagents.

To further help you maximize the potential of your research and streamline your transition to the clinic, we offer Gibco Cell Therapy Systems (CTS) equivalents for many of our research-use products. In addition to GMP manufacturing, Gibco CTS products undergo quality control testing and are accompanied by appropriate documentation so you can transition your cell therapy to the clinic with confidence.

*Adherence to supplier related responsibilities of USP<1043>

First off-the-shelf reprogramming system manufactured in accordance with GMP requirements. CTS CytoTune 2.1 kit offers high-efficiency Sendai delivery of reprogramming factors.

Click image to enlarge

Efficient reprogramming from adult human dermal fibroblasts, T cells, and CD34+ cells. These data demonstrate that the CytoTune-iPS 2.1 kit can be used to successfully reprogram human dermal fibroblasts (HDFa), T cells, and CD34+ cells.

Gibco CTS Essential 6 Medium is a xeno-free, feeder-free, cGMP-manufactured medium which supports the spontaneous or directed differentiation of human pluripotent stem cells (PSCs) and the reprogramming of somatic cells.

Based on the widely cited Gibco Essential 8 Medium, Gibco CTS Essential 8 Medium is the first globally available human- and animal originfree culture medium for human pluripotent stem cells (hPSCs) and is designed to meet international regulatory requirements for cell therapy.

Click image to enlarge

Using Applied Biosystems TaqMan hPSC Scorecard Panel analysis, Gibco CTS Essential 8 Medium and research-use-only Essential 8 Medium were shown to support comparable expression of PSC markers and lineage markers in undifferentiated PSCs and PSC-derived embryoid bodies.

CTS Vitronectin (VTN-N) Recombinant Human Protein is a defined matrix for feeder-free culture of iPSCs. Designed in the laboratory of James Thomson, this recombinant protein is intended for use with the CTS Essential 8 culture system.

CTS RevitaCell Supplement (100X) is an animal-origin-free, chemically defined supplement used with PSCs for post-thaw recovery or in combination with CTS Essential 8 Medium for single cell passaging. To minimize both the loss of cell viability and differentiation of PSCs, use the CTS PSC Cryopreservation Kit.

CTS Versene is a gentle non-enzymatic cell dissociation reagent for use in routine clump passaging of PSCs while maintaining viability over multiple passages.

For the cryopreservation and recovery of PSCs, the CTS PSC Cryopreservation Medium and CTS RevitaCell Supplement minimize the loss of cell viability and maximize post-thaw recovery when used in combination. Both reagents are included in the CTS PSC Cryopreservation Kit.

The CTS PSC Cryopreservation Medium is a xeno-free solution for the cryopreservation of pluripotent stem cells (PSCs). Both CTS PSC Cryopreservation Medium and CTS RevitaCell supplement are included in the CTS PSC Cryopreservation Kit that helps minimize loss of cell viability and maximize post-thaw recovery.

CTS KnockOut SR XenoFree Medium is a defined, xeno-free serum replacement based on the traditional Gibco KnockOut Serum Replacement, which has been cited in more than 2,000 publications and trusted for over 20 years.

Maintenance of pluripotency using CTS KNOCKOUT SR XenoFree Medium. Following 10 passages in either KSR (left lane) or KSR XenoFree CTS (right lane) on HFF attached with CELLstart substrate, BG01v gene expression was examined (top). Gene expression of embryoid bodies generated from the same P10 BG01v/HFF cultures (bottom).

Your choice of chemically defined human- and animal origin-free basal media for pluripotent stem cell culture. Based on traditional DMEM and DMEM/F12 formulations, these basal media are:

We offer full customization options to help meet your unique specifications for any project. Flexibility is yours in creating your own Gibco custom cell culture medium

Intended use of the products mentioned on this page vary. For specific intended use statements please refer to the product label.

View original post here:
Induced Pluripotent Stem Cell (iPSC) Media and Reagents ...

IPS Cell Therapy Comments Off on Induced Pluripotent Stem Cell (iPSC) Media and Reagents … | April 27th, 2020